Evidence map›Paper›PMID 39671164›Full record

ArticleAnnals of surgical oncology2025

Aggressive Multidisciplinary Treatment for Unresectable Hepatocellular Carcinoma: The Achievement of a Pathologic Complete Response and Long-Term Survival.

Takuma Karasuyama, Takamichi Ishii, Tomoaki Yoh, Satoshi Ogiso, Haruhiko Takeda, Atsushi Takai, Noriko Kishi, Hironori Shimizu, Takashi Ito, Hironori Haga and 1 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takuma Karasuyama *Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takamichi Ishii *Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. taishii@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-7461-9653
Tomoaki YohDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Satoshi OgisoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Haruhiko TakedaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Atsushi TakaiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Noriko KishiDepartment of Radiation Oncology, Kyoto University Hospital, Kyoto, Japan.
Hironori ShimizuDepartment of Radiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takashi ItoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hironori HagaDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Etsuro HatanoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) with inferior vena cava (IVC) tumor thrombus is generally considered to be borderline resectable because of its poor prognosis.

methodsThe 56-year-old woman in this study had diffuse HCC of the medial and anterior segments. She received an explanation of the procedure and provided informed consent. A tumor thrombus was observed in the right atrium through the middle and left hepatic veins and in the anterior branch of the portal vein. The HCC was considered unresectable, and atezolizumab plus bevacizumab combination therapy was initiated. However, the tumor thrombus progressed to the right atrium after two courses. The treatment was changed to hepatic arterial infusion chemotherapy with cisplatin and three-dimensional conformal radiotherapy to the tumor thrombus in the right atrium, followed by systemic lenvatinib.

resultsThe patient's tumor marker levels decreased significantly, and the tumor thrombus regressed into the IVC. Left hepatic trisegmentectomy and IVC tumor thrombectomy were performed.

conclusionThis report presents a case of unresectable HCC treated with multimodality therapy followed by salvage surgery. The patient achieved a long-term cancer-free and drug-free status through aggressive treatment. This patient's experience offers hope for aggressive treatment of advanced HCC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularLiver NeoplasmsVena Cava, InferiorCisplatinCombined Modality TherapyFemaleHepatectomyHumansMiddle AgedPathologic Complete ResponsePhenylurea CompoundsPrognosisQuinolinesRadiotherapy, ConformalSurvival RateCisplatinlenvatinibPhenylurea CompoundsQuinolines

Identifiers

PMID39671164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.